These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30746797)

  • 1. Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients.
    Egawa G; Honda T; Kabashima K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):259. PubMed ID: 30746797
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
    Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis.
    Ito M; Kamata M; Uchida H; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Tada Y
    Br J Dermatol; 2022 Nov; 187(5):793-795. PubMed ID: 35661135
    [No Abstract]   [Full Text] [Related]  

  • 6. Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient.
    Megna M; Abategiovanni L; Annunziata A; Torta G; Peduto T; Fabbrocini G; Lauro W
    Dermatol Ther; 2022 May; 35(5):e15382. PubMed ID: 35170168
    [No Abstract]   [Full Text] [Related]  

  • 7. Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab.
    Huang D; Liu T; Li J; Lu Y; Ma H
    Dermatol Ther; 2022 Dec; 35(12):e15878. PubMed ID: 36181408
    [No Abstract]   [Full Text] [Related]  

  • 8. Guillain-Barré syndrome is associated with ixekizumab in a patient with pustular psoriasis.
    Liu H; Li Q; Li Q; Li X; Dai L
    Rheumatology (Oxford); 2023 May; 62(5):e161-e163. PubMed ID: 36269188
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of erythrodermic psoriasis successfully treated with ixekizumab.
    Megna M; Gallo L; Balato N; Balato A
    Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis.
    Avallone G; Cariti C; Dapavo P; Ortoncelli M; Conforto L; Mastorino L; Roccuzzo G; Cavallo F; Rubatto M; Quaglino P; Ribero S
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e574-e576. PubMed ID: 35279885
    [No Abstract]   [Full Text] [Related]  

  • 12. Two cases of generalized pustular psoriasis successfully treated with bimekizumab.
    Hagino T; Saeki H; Kanda N
    J Dermatol; 2023 Oct; 50(10):e357-e358. PubMed ID: 37334759
    [No Abstract]   [Full Text] [Related]  

  • 13. Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab.
    Akaji K; Nakagawa Y; Kakuda K; Takafuji M; Kiyohara E; Murase C; Takeichi T; Akiyama M; Fujimoto M
    J Dermatol; 2021 Jan; 48(1):e43-e44. PubMed ID: 33063316
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis.
    Ran D; Yang B; Sun L; Wang N; Qu P; Liu J; Pan F; Wang G; Wu W; Zhang Z; Shi Z; Yang Q; Liu H; Zhang F
    Clin Exp Dermatol; 2023 Jul; 48(7):803-805. PubMed ID: 36994823
    [No Abstract]   [Full Text] [Related]  

  • 15. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
    Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with secukinumab in a patient with generalized pustular psoriasis preceded by palmoplantar lesions.
    Sawai N; Kawakami Y; Tachibana K; Nomura H; Miyake T; Yokoyama E; Hirai Y; Morizane S
    J Dermatol; 2023 Dec; 50(12):e413-e414. PubMed ID: 37577828
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
    Plachouri KM; Chourdakis V; Georgiou S
    Drugs Today (Barc); 2019 Sep; 55(9):587-593. PubMed ID: 31584575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical nail psoriasis induced by the IL-17A inhibitor ixekizumab in palmoplantar pustulosis.
    André R; Boehncke WH; Laffitte E
    Int J Dermatol; 2023 Jul; 62(7):e370-e371. PubMed ID: 37057631
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
    Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
    J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
    Langley RG; Kimball AB; Nak H; Xu W; Pangallo B; Osuntokun OO; Agada N; Reich K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):333-339. PubMed ID: 30198588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.